Wonkwang University (President Maeng-Soo Park) In-Am Brain Research Center (Director Son Il-Hong), affiliated with Sanbon Hospital, is attracting attention by suggesting a new treatment for Parkinson’s disease.
According to the In-Am Brain Research Center on the 15th, it revealed a pathway that accelerates the degradation of alpha-synuclein, which has been identified as a major causative agent of Parkinson’s disease, using a protein called nucleolin.
Alpha-synuclein (α-synuclein) is one of the normal proteins present in the brain. It is responsible for the secretion of neurotransmitters such as dopamine at the ends of nerve cells, but it is abnormally aggregated in cranial nerve cells or glial cells due to environmental or genetic factors. It is known to cause Parkinson’s disease, Lewy body dementia, and multiple system atrophy.
In addition, nucleolin is a protein that is specifically overexpressed on the surface of cancer cells, and has been attracting great attention in the medical community as a bio-marker that predicts and diagnoses the risk of tumors. This is the first time that a new possibility has been proposed as a therapeutic agent that can accelerate the breakdown of Klein protein.
A paper containing such research achievements was published in the SCI International Journal of Neurobiology of Disease, which ranks in the top 10% of the field under the theme of’Nucleoline promotes the decomposition of alpha-synuclein accumulated in animal models’. Will be.
In addition, the In-Am Neurology Research Center analyzed the results of a study of patient urine samples and brain tissues distributed from Seoul National University Brain Bank in June of last year and February of this year to detect and evaluate alpha-synuclein polymers in the urine of Parkinson’s disease patients. ‘,’Analysis of the amount of alpha-synuclein associated with LRRK2 kinase in the striatum and urine of Parkinson’s disease patients’. System).
On the other hand, the In-Am Brain Research Center affiliated with Wonkwang University Sanbon Hospital, following the will of the late founder In-Am Yoon Sung-gyun, has been devoted to research on Parkinson’s disease in order to meet the establishment’s purpose of revitalizing the treatment and research of Parkinson’s disease in the local community since 2005. / Iksan =Reporter Kim Ik-gil·kimtop1210@
Reporter Kim Ik-gil [email protected]
<저작권자 © 전라일보, 무단 전재 및 재배포 금지>